Serum uric acid levels in patients with multiple sclerosis: a meta-analysis
The DOI matches its Crossref record.
Abstract
BACKGROUND: Serum uric acid (UA), a natural scavenger of peroxynitrite, has been found to be of lower levels in patients with multiple sclerosis (MS) in some recent preliminary studies. OBJECTIVE: To evaluate the correlation between serum UA levels and several clinical parameters of MS reliably. METHODS: We surveyed studies on the serum UA levels and MS patients with comprehensive search and review of the references. A meta-analysis was performed to demonstrate the potential association between serum UA levels in MS patients and their clinical characteristics by random effects models. Results The serum UA levels were lower in patients with MS than in healthy controls (standardized mean difference (SMD) = -0·68; 95% confidence interval (CI): -0·82 to -0·55), as well as in other inflammatory neurological diseases (OINDs) (SMD = -0·45; 95% CI: -0·60 to -0·30). Similarly, the serum UA levels decreased in MS patients with clinical activity when compared to MS with clinical inactivity (SMD = -0·29; 95% CI: -0·48 to -0·10), as well as in relapsing-remitting MS (RRMS) patients with relapse in comparison to RRMS patients with remission (SMD = 0·64; 95% CI: 0·39 to 0·89). However, the results suggested that serum UA levels did not correlate with higher (or lower) expanded disability status scale (SMD = -0·09; 95% CI: -0·10 to 0·27) and magnetic resonance imaging (MRI) activity (SMD = -0·14; 95% CI: -0·13 to 0·41). In the subtypes of MS group, there were significant differences in serum UA levels between secondary progressive MS (SPMS) and RRMS (SMD = -0·34; 95% CI: 0·16 to 0·52), or primary progressive MS (PPMS) (SMD = -0·58; 95% CI: -0·89 to -0·27), but no significant difference between RRMS and PPMS (SMD = -0·18; 95% CI: -0·44 to 0·08). CONCLUSIONS: Our study suggests that UA is relevant to MS. Future research is needed to determine whether the administration of UA levels by inosine might be considered as a novel treatment strategy for MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P. A., & Tzoulaki, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70267-4 · Cited by 671
Uric acid as a danger signal in gout and its comorbidities
Rock, K. L., Kataoka, H., & Lai, J.-J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.143 · Cited by 444
Li, X., Meng, X., Timofeeva, M., Tzoulaki, I., Tsilidis, K. K., Ioannidis, P. A., Campbell, H., & Theodoratou, E. (2017) · BMJ · doi:10.1136/bmj.j2376 · Cited by 385
The Role of the Inflammasome in Neurodegenerative Diseases
Piancone, F., La Rosa, F., Marventano, I., Saresella, M., & Clerici, M. (2021) · Molecules · doi:10.3390/molecules26040953 · Cited by 144
Metadata
- Authors
- Liu, B., Shen, Y., Xiao, K., Tang, Y., Cen, L., & Wei, J.
- Venue
- Neurological Research
- Publisher
- Informa UK Limited
- Published
- 2012-03
- Volume
- 34
- Issue
- 2
- Pages
- 163-171
- ISSN
- 0161-6412 (ISSN-L)
- 1743-1328
- OpenAlex
- W2051214947
- Cited by
- 69
- References
- 0
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. https://app.cochat.ai/papers/10.1179/1743132811y.0000000074
- The paper
- Liu, B., Shen, Y., Xiao, K., Tang, Y., Cen, L., & Wei, J. (2012). Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurological Research. https://doi.org/10.1179/1743132811y.0000000074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.